Ignite Creation Date:
2025-12-24 @ 5:47 PM
Ignite Modification Date:
2025-12-27 @ 1:28 AM
Study NCT ID:
NCT01613768
Status:
COMPLETED
Last Update Posted:
2018-09-28
First Post:
2012-06-05
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer
Sponsor:
University of Washington
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2012-05-08
Start Date Type:
ACTUAL
Primary Completion Date:
2017-08-23
Primary Completion Date Type:
ACTUAL
Completion Date:
2017-08-23
Completion Date Type:
ACTUAL
First Submit Date:
2012-06-05
First Submit QC Date:
None
Study First Post Date:
2012-06-07
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2018-07-10
Results First Submit QC Date:
None
Results First Post Date:
2018-08-10
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-08-30
Last Update Post Date:
2018-09-28
Last Update Post Date Type:
ACTUAL